Cargando…
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab
IMPORTANCE: Increased survival with immune checkpoint inhibitors has been reported for patients with obesity vs a normal body mass index (BMI). However, the association of obesity with the safety of immune checkpoint inhibitors warrants study. OBJECTIVE: To investigate associations between BMI and i...
Autores principales: | McQuade, Jennifer L., Hammers, Hans, Furberg, Helena, Engert, Andreas, André, Thierry, Blumenschein, George, Tannir, Nizar, Baron, Ari, Larkin, James, El-Khoueiry, Anthony, Carbone, David P., Thomas, John-Michael, Hennicken, Delphine, Coffey, Mary, Motzer, Robert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857666/ https://www.ncbi.nlm.nih.gov/pubmed/36480191 http://dx.doi.org/10.1001/jamaoncol.2022.5409 |
Ejemplares similares
-
Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023) -
Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2022) -
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022) -
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022) -
Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody
por: Bilen, Mehmet Asim, et al.
Publicado: (2016)